Kite Therapeutics, a Gilead Company, has entered into a definitive agreement to acquire Interius Therapeutics to complement its expertise in cell therapy by incorporating Interius’ integrating in vivo platform. This approach enables the generation of CAR T-cells directly within the patient’s body and may offer a more durable and long-lasting therapeutic effect by inserting DNA into the patient’s genome. Interius was co-founded by Saar Gill, MD, PhD, Associate Professor at Penn Medicine. Read more here and here.